Sarepta Therapeutics Inc. is a biopharmaceutical company dedicated to developing precision genetic medicine for the treatment of rare neuromuscular diseases. With an emphasis on RNA-targeted therapeut... Sarepta Therapeutics Inc. is a biopharmaceutical company dedicated to developing precision genetic medicine for the treatment of rare neuromuscular diseases. With an emphasis on RNA-targeted therapeutics, Sarepta's primary focus is on Duchenne muscular dystrophy (DMD), a severe and progressive muscle degeneration disorder. The company's pipeline features innovative gene therapy and RNA-based technologies designed to address the underlying genetic cause of DMD, offering potential to alter the disease trajectory. Sarepta Therapeutics engages primarily with the healthcare and life sciences industries, collaborating with academic institutions and leveraging advanced bioinformatics tools for drug discovery and development. Situated at the forefront of genetic medicine, Sarepta plays a significant role in pioneering treatments that could revolutionize care for rare diseases, making substantial impacts on both patients' lives and the broader biopharmaceutical landscape.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

Sarepta Therapeutics is not subject to EU Taxonomy reporting

Based on current regulatory requirements, Sarepta Therapeutics is not required to report EU Taxonomy data under the CSRD framework. As a result, we have not conducted a detailed EU Taxonomy data review for this company.

If you believe this assessment should be revisited, you may submit a data coverage request and our team will review the company's regulatory applicability.

Would you like us to review Sarepta Therapeutics's data?

Create a free Tracenable account to signal interest in having our team review data for Sarepta Therapeutics.

Legal Center Contact Us